Insider Selling: Biogen Idec SVP Sells 4,000 Shares of Stock (BIIB)
Biogen Idec (NASDAQ:BIIB) SVP Raymond Pawlicki sold 4,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $238.03, for a total value of $952,120.00. Following the sale, the senior vice president now directly owns 8,710 shares of the company’s stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
A number of research firms have recently commented on BIIB. Analysts at Goldman Sachs Group Inc. raised their price target on shares of Biogen Idec (NASDAQ:BIIB) from $220.00 to $240.00 in a research note to investors on Wednesday. Separately, analysts at Zacks upgraded shares of Biogen Idec (NASDAQ:BIIB) from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday. They now have a $288.00 price target on the stock. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Biogen Idec (NASDAQ:BIIB) in a research note to investors on Tuesday.
Nine equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $250.23.
Biogen Idec (NASDAQ:BIIB) traded up 2.62% during mid-day trading on Wednesday, hitting $246.346. 1,606,903 shares of the company’s stock traded hands. Biogen Idec has a one year low of $134.00 and a one year high of $242.64. The stock’s 50-day moving average is $219.1 and its 200-day moving average is $211.2. The company has a market cap of $58.549 billion and a P/E ratio of 35.56.
Biogen Idec (NASDAQ:BIIB) last posted its quarterly earnings results on Thursday, July 25th. The company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.93 by $0.37. The company had revenue of $1.70 billion for the quarter, compared to the consensus estimate of $1.62 billion. During the same quarter in the previous year, the company posted $1.82 earnings per share. The company’s revenue for the quarter was up 21.3% on a year-over-year basis. On average, analysts predict that Biogen Idec will post $8.58 earnings per share for the current fiscal year.
Biogen Idec Inc (NASDAQ:BIIB) is a global biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.